Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome

References

• Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51:1086–1092.
   PubMed Web of Science ®Google Scholar
• Greenberg PL. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. J Natl Compr Canc Netw. 2013;11:877–884.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–69.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021–4034.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118:6239–6246.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92:744–752.
   PubMed Web of Science ®Google Scholar
• Mihara K, Takihara Y, Kimura A. Genetic and epigenetic alterations in myelodysplastic syndrome. Cytogenet Genome Res. 2007;118:297–303.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117:2697–2702.
   PubMed Web of Science ®Google Scholar
• Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012;30:4533–4540.
   PubMed Web of Science ®Google Scholar
• Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007;67:1419–1423.
   PubMed Web of Science ®Google Scholar
• Nie K, Zhang T, Allawi H, et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol. 2010;177:1470–1479.
   PubMed Web of Science ®Google Scholar
• Li Y, Lin J, Yang J, et al. Overexpressed Let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013;37:1642–1647.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 88–93.
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Qian J, Zhu ZH, Lin J, et al. Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. Br J Haematol. 2011;154:153–155.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–543.
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–3756.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635–647.
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–198.
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Tanaka K, Kawano M, et al. Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells. Int J Oncol. 2015;46:1543–1550.
   PubMed Web of Science ®Google Scholar
• Kelly BD, Miller N, Sweeney KJ, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J Clin Med. 2015;4:1369–1379.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhang C, Li T, et al. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol. 2015;46:2526–2534.
   PubMed Web of Science ®Google Scholar
• Colamaio M, Calì G, Sarnataro D, et al. Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene. J Clin Endocrinol Metab. 2012;97:E2168–E2178.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin JY, Lee KD, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012;14:R14.
   PubMed Web of Science ®Google Scholar
• Lu L, Katsaros D, Risch HA, et al. MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer. Mol Carcinog. 2016;55:357–365.
   PubMed Web of Science ®Google Scholar
• Haldrup C, Kosaka N, Ochiya T, et al. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv Transl Res. 2014;4:19–30.
   PubMed Web of Science ®Google Scholar
• Schubert M, Spahn M, Kneitz S, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One. 2013;8:e65064.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Zhang Y, et al. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010;59:579–585.
   PubMed Web of Science ®Google Scholar
• Vickers MM, Bar J, Gorn-Hondermann I, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis. 2012;29:123–132.
   PubMed Web of Science ®Google Scholar
• Zuo Z, Calin GA, de Paula HM, et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood. 2011;118:413–415.
   PubMed Web of Science ®Google Scholar
• Lu L, Katsaros D, de la Longrais IA, et al. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007;67:10117–10122.
   PubMed Web of Science ®Google Scholar
• Lu L, Katsaros D, Zhu Y, et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat. 2011;126:687–694.
   PubMed Web of Science ®Google Scholar
• Ko YC, Fang WH, Lin TC, et al. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia. Leuk Res. 2014;38:625–631.
   PubMed Web of Science ®Google Scholar
• Zhu XW, Yao DM, Wu DH, et al. Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia. Tumour Biol. 2016;37:491–501.
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361:1475–1485.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Agrelo R, Esteller M. Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci. 2007;1100:60–74.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choi Y, Kim SD, et al. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. Eur J Haematol. 2015;94:546–553.
   PubMed Web of Science ®Google Scholar
• Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood. 2009;113:659–667.
   PubMed Web of Science ®Google Scholar
• Qin T, Castoro R, El Ahdab S, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One. 2011;6:e23372.
   PubMed Web of Science ®Google Scholar